Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Clinical Results in Primary Sclerosing Cholangitis and Hepatitis Delta Transcript

Operator

Good morning, and welcome to Mirum Pharmaceuticals Business Update Call. My name is Ben, and I will be your operator today. [Operator Instructions] I would now like to hand the conference over to Andrew McKibben, SVP of Strategic Finance and Investor Relations. Please go ahead.

Andrew McKibben
Senior Vice President, Strategic Finance & Investor Relations

Thank you, Ben, and good morning, everyone. I’m very happy to welcome you to Mirum’s conference call to discuss our recent clinical readouts, including the top line results of our VISTAS Phase IIb study of volixibat in patients with primary sclerosing cholangitis, or PSC, and last week’s announcement of top line results from the Phase II portion of the AZURE-1 study of brelovitug in hepatitis delta. For our prepared remarks, I’m joined today by our CEO, Chris Peetz; and our Chief Medical Officer, Joanne Quan. I’m also joined by our President and Chief Operating Officer, Peter Radovich; and our Chief Financial Officer, Eric Bjerkholt, who will both be available for Q&A. The call will begin with opening remarks from Chris, followed